GCA
PCRX icon

Greenwood Capital Associates’s Pacira BioSciences PCRX Stock Holding History

Greenwood Capital Associates’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$553K Sell
21,796
-999
-4% -$23.6K 0.05% 208
2026
Q1 		$515K Buy
22,795
+3,471
+18% +$77.1K 0.06% 198
2025
Q4 		$500K Buy
19,324
+4,426
+30% +$105K 0.05% 191
2025
Q3 		$384K Buy
14,898
+1,742
+13% +$42.8K 0.04% 215
2025
Q2 		$314K Buy
+13,156
New +$332K 0.04% 225

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Greenwood Capital Associates's PCRX Position: Q2 2026 in Review

Greenwood Capital Associates reduced its Pacira BioSciences (PCRX) stake by 4.4% in Q2 2026, selling an estimated $23.6K and leaving 21,796 shares worth $553K. The position accounts for 0.05% of the portfolio, ranked #208.

Greenwood Capital Associates first reported a position in PCRX in Q2 2025 and has held it in 5 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Greenwood Capital Associates held 21,796 shares of Pacira BioSciences worth $553K as of Q2 2026.
  • Greenwood Capital Associates sold 999 Pacira BioSciences shares in Q2 2026, an estimated $23.6K.
  • Pacira BioSciences made up 0.05% of Greenwood Capital Associates's portfolio in Q2 2026, its #208 holding.
  • Greenwood Capital Associates first reported a position in Pacira BioSciences in Q2 2025 and has held it in 5 quarters since.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.